Clinical Trial Update: Nivolumab in Biochemically Recurrent dMMR Prostate Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial of nivolumab in biochemically recurrent, mismatch repair-deficient prostate cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• nivolumab (nivolumab)

Snippet

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Conditions: Prostate Cancer, Recurrent Prostate Cancer | Phase 2 | Status: COMPLETED